103392-12-7

Basic information

• Product Name: 2-Hexanone, 5-methyl-3-phenyl-
• CAS NO: 103392-12-7
• Molecular Formula: C13H18O
• Molecular Weight: 190.285
• Mol File: 103392-12-7.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 2-Hexanone, 5-methyl-3-phenyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Hexanone, 5-methyl-3-phenyl-(103392-12-7)
• EPA Substance Registry System: 2-Hexanone, 5-methyl-3-phenyl-(103392-12-7)

Safety Data

• Hazardous Substances Data: 103392-12-7(Hazardous Substances Data)

Upstream product

• 513-38-2 Isobutyl iodide 
• 103-79-7 1-phenyl-acetone 
• 917-64-6 methyl magnesium iodide 
• 14320-58-2 4-methyl-2-phenyl-n-pentanoic acid 
• 103-82-2 phenylacetic acid 
• 605680-32-8 N-methoxy-N-methyl-4-methyl-2-phenylpentanamide 
• 75-16-1 methylmagnesium bromide 
• 78-77-3 Isobutyl bromide 
• 63866-06-8 1-Phenyl-2-propanone Dianion 
• 705-60-2 1-phenyl-2-nitroprop-1-ene 
• 100-99-2 triisobutylaluminum 
• 57918-71-5 1-Phenyl-2-propanone Potassium Enolate 

Downstream Products

• 610791-34-9 2-amino-5-methyl-3-phenylhexane 
• 605680-34-0 2-azido-5-methyl-3-phenylhexane 
• 605680-33-9 5-methyl-3-phenyl-2-hexanol 

Relevant articles and documents

SUBSTITUTED SULFONAMIDES

The substituted sulfonamides of the invention are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

SUBSTITUTED ARYL AMIDES

Novel compounds of structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as, the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

Formation and Reactions of 1-Phenyl-2-propanone Dianion and Related Systems with Electrophilic Reagents

1-Phenyl-2-propanone, 1,1-diphenyl-2-propanone, and 1-(4-methoxyphenyl)-2-propanone were converted to their dicarbanions 3, 4, and 31, respectively, and their reactions with a number of electrophilic reagents were examined.All three dianions gave a mixture of C-1 and C-3 alkylation products when treated with alkyl halides of higher reactivity, while only C-1 alkylations occurred when alkyl halides of lower reactivity were used.It was also found that the 1,1-diphenyl-2-propanone and the 1-(4-methoxyphenyl)-2-propanone dianions 4 and 31 gave a higher ratio of C-1/C-3 alkylation products than the 1-phenyl-2-propanone dianion 3.When dianion 3 was reacted with p-anisaldehyde and a number of protonating agents, electrophilic attack occurred exclusively at the C-3 position.The trends observed are analyzed, and mechanisms are proposed to account for the results obtained.